Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1997-03-12
1999-12-21
Brusca, John S.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
435 9141, 4353201, 536 231, 536 2372, C12P 2100, C12N 1563, C12N 1566, C12N 1511
Patent
active
060047771
ABSTRACT:
Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector or at different loci. The second nucleic acid molecule can encode encode one translation factor or more than one translation factor. The translation factor can be a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus; for instance, a NYVAC vaccinia virus or an ALVAC canarypox virus.
REFERENCES:
patent: 5494807 (1996-02-01), Paoletti et al.
Piccini et al. Vaccinia Virus as an Expression Vector. Methods in Enzymology vol. 153 pp. 545-563, 1987.
Beattie et al. Journal of Virology, vol. 69, No. 1, Jan. 1995, pp. 499-505.
Ahn, B-Y. and Moss, B. 1992. RNA polymerase-associated transcription specificity factor encoded by vaccinia virus. Proc. Natl. Acad. Sci. 89: 3536-3540.
Beattie, E., Paoletti, E., and Tartaglia, J. 1995. Distinct Patterns of IFN Sensitivity Observed in Cells Infected with Vaccinia K3L and E3L Mutant Viruses. Virology 210:254-263.
Beattie, E., Tartaglia, J. and Paoletti, E. 1991, Vaccinia virus-encoded eIF-2a homologue abrogates the antiviral effect of interferon. Virology 183: 419-422.
Carroll, K., Elroy Stein, O., Moss, B. and Jagus, R. 1993. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. J. Biol. Chem. 268: 12837-12842.
Chang, H-W., Watson, J. and Jacobs, B. L. 1992. The vaccinia virus E3L gene encodes a double-stranded RNA-binding protein with inhibitory activity for the interferon-induced protein kinase. Proc. Natl. Acad. Sci. USA 89: 4825-4829.
Clark, P. A., Schwemmle, M., Schickinger, J., Hilse, K., and Clemens, M. J. 1991. Binding of Epstein-Barr virus small RNA EBER-1 to double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res. 19:243-248.
Davies. M. V., Chang, H. W. , Jacobs, B. L. and Kaufman, R. J. 1993. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67: 1688-1692.
Davies, M. V., Elroy Stein, O., Jagus, R., Moss, B. and Kaufman, R. J. 1992. The vaccinia K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J. Virol. 66: 1943-1950.
Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, J. P. and Paoletti, E. 1990. The complete DNA sequence of vaccinia virus. Virology 179: 247-266.
Harlow, E. and Lane, D. (1988). Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory. 421-470.
Hattori, M., and Sakaki, Y. (1986). Dideoxy sequencing method using denatured plasmid templates. Anal. Biochem. 152, 232-237.
Imani, F. and Jacobs, B. L. 1988. Inhibitory activity for the interferon induced protein Kinase is associated with the reovirus serotype 1 s3 protein. Proc. Natl. Acad. Sci. USA 85: 7887-7891.
Jacobs, B. L. and Langland, J. O. 1996. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 219: 339-349.
Langone, J. (1982). Applications of immobilized protein A in immunochemical techniques. J. Immunol. Methods. 55. 277-296.
Mathews, M. B. and Shenk, T. 1991. Adenovirus virus-associated RNA and translation control. J. Virol. 65: 5657-5662.
Moss, B. 1990. Regulation of vaccinia virus transcription. Annu. Rev. Biochem. 59: 661-688.
Moss, B. 1992. Molecular biology of poxviruses. In Recombinant Poxviruses. Binns M. M., Smith, G. L. (eds). Boca Raton, FL: CRC Press; pp. 45-80.
Park, H., Davies, M. V., Langland, L. O., Chang, H-W., Nam, Y. S., Tartaglia, J., Paoletti, E., Jacobs, B. L., Kaufman, R. J. and Venkatesan, S. 1994. Proc. Natl. Acad. Sci. USA 91: 4713-4717.
Perkus, M., Limbach, K., Paoletti, E. (1989). Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virology 63. 3829-3836.
Perkus, M. E., Tartaglia, J., and Paoletti, E. 1995. Poxvirus-based vaccine candidates for cancer, AIDS and other infectious diseases. J. of Leukocyte Biology 58: 1-13.
Sharp, T. V., Schwemmle, M., Jeffrey, I., Laing, K., Mellor, H., Proud, C. G., Hilse, K. and Clemens, M. J. 1993. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res. 21: 4483-4490.
Tabor, S., and Richardson, C.C. (1987). DNA sequence analysis with a modified bacteriophage T7 polymerase. Proc. Natl. Acad. Sci. USA 84, 4767-4771.
Tartaglia, J., Perkus, M. E., Taylor, J. et al. 1992. NYVAC: A highly attenuated strain of vaccinia virus. Virology 188: 217-232.
Thimmappaya, B. C., Weinberger, C., Schneider, R. J. and Shenk, T. 1982. Adenovirus VAI RNA is required for efficient translation viral mRNAs at late times after infection. Cell 31: 543-551.
Watson, J., Chang, H-W. and Jacobs, B. L. 1991. Characterization of a vaccinia virus-induced dsRNA-binding protein that may be the inhibitor of the dsRNA-dependent protein kinase. Virology 185: 206-216.
Yuen, L, and Moss, B. (1987). Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA 84, 6417-6421.
Zhang, Y., Ahn, B-Y. and Moss, B. 1994. Targeting of a multicomponent transcription apparatus into assembling vaccinia virus particles requires RAP94, an RNA polymerase-associated protein. J. Virol. 68: 1360-1370.
Cox William I.
Gettig Russell Robert
Goebel Scott J.
Jacobs Bertram L.
Paoletti Enzo
Arizona State University
Brusca John S.
Frommer William S.
Kowalski Thomas J.
Virogenetics Corporation
LandOfFree
Vectors having enhanced expression, and methods of making and us does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vectors having enhanced expression, and methods of making and us, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectors having enhanced expression, and methods of making and us will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-503801